Mobile-health Network Solutions

Mobile-health Network Solutions(MNDR)股票分析

$1.530

-0.039 (-2.55%)收盘时

Loading chart…
High
1.590
Open
1.570
VWAP
1.54
Vol
38.85K
Mkt Cap
Low
1.500
Amount
59.84K
EV/EBITDA, TTM
0.00

Mobile-health Network Solutions is an artificial intelligence (AI)-powered digital health platform, with operations across Southeast Asia and expanding into the United States. The Company provides telemedicine, AI-driven health tools, and virtual clinic infrastructure to empower patients and doctors worldwide. The Company's MaNaDr platform is a 360-degree healthcare ecosystem which connects users and service providers through the range of healthcare services and product offerings that can be accessed through the mobile application and website. The healthcare solutions offered on its MaNaDr platform primarily encompass: MaNaDr Mobile Application, MaNaPharma, MaNaShop/MaNaStore, and MaNaCare. It offers teleconsultation services over its MaNaDr mobile application, through online consultations provided by its in-house medical team and external doctors from its network of clinic service providers. MaNaPharma includes B2B sales to clinics and other healthcare service providers.

AI analysis of Mobile-health Network Solutions (MNDR)

buy

Mobile-health Network Solutions (MNDR) is a good buy right now due to its recent acquisition news and potential for recovery. The current price is $1.55, which is significantly lower than its historical average SMA of $5.599, indicating a potential undervaluation. Additionally, the stock has a projected final change of +142.85% based on similar historical patterns, suggesting strong upside potential. However, the main risk is the negative earnings per share (EPS) of -3.07 reported for Q2 2026, indicating ongoing financial challenges.

估值指标

The current forward P/E ratio for Mobile-health Network Solutions (MNDR) is 0.00, compared to its 5-year average forward P/E of -13.23.

Forward P/E

Fair
5Y Average P/E
-13.23
Current P/E
0.00
高估
23.13
低估
-49.59

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-11.33
Current EV/EBITDA
0.00
高估
26.12
低估
-48.79

Forward P/S

Fair
5Y Average P/S
3.36
Current P/S
0.00
高估
14.72
低估
-8.01

Alphio AI Price Scenarios for MNDR

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MNDR

$1.16

情景价格

B

Base

Base · 50%MNDR

$1.10

情景价格

B

Bear

Bear · 25%MNDR

$0.87

情景价格

事件时间线

2026-06-26 (ET)

20:00:00

Mobile-Health Network Solutions Trading Halted, News Pending

2026-03-09 (ET)

06:20:00

Offering for Selling Shareholders

2025-07-16 (ET)

11:03:30

Mobile-health Network Solutions files $300M mixed securities shelf

2025-03-21 (ET)

17:18:54

Mobile-health Network Solutions files to sell 3.34M Class A ordinary shares

2024-12-17 (ET)

07:35:44

Mobile-health Network Solutions launches ManaSocial platform

资讯

MNDR FAQ — answered by Alphio AI

Mobile-health Network Solutions is an artificial intelligence (AI)-powered digital health platform, with operations across Southeast Asia and expanding into the United States. The Company provides telemedicine, AI-driven health tools, and virtual clinic infrastructure to empower patients and doctors worldwide. The Company's MaNaDr platform is a 360-degree healthcare ecosystem which connects users and service providers through the range of healthcare services and product offerings that can be accessed through the mobile application and website. The healthcare solutions offered on its MaNaDr platform primarily encompass: MaNaDr Mobile Application, MaNaPharma, MaNaShop/MaNaStore, and MaNaCare. It offers teleconsultation services over its MaNaDr mobile application, through online consultations provided by its in-house medical team and external doctors from its network of clinic service providers. MaNaPharma includes B2B sales to clinics and other healthcare service providers. It operates in the Technology sector (PREPACKAGED SOFTWARE industry).

Mobile-health Network Solutions (MNDR) is a good buy right now due to its recent acquisition news and potential for recovery. The current price is $1.55, which is significantly lower than its historical average SMA of $5.599, indicating a potential undervaluation. Additionally, the stock has a projected final change of +142.85% based on similar historical patterns, suggesting strong upside potential. However, the main risk is the negative earnings per share (EPS) of -3.07 reported for Q2 2026, indicating ongoing financial challenges.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始